Papillary Carcinoma of the Breast
Papillary Carcinoma is a type of ductal carcinoma in situ (DCIS). This type of breast cancer is rarely invasive, and usually stays within the milk ducts of your breast. It has a good chance of recovery after treatment. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 19, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Lobular Carcinoma in situ - LCIS
A definition and description of lobular carcinoma in situ, with signs and symptoms, and treatment. Learn more about lobular carcinoma in situ (LCIS) here. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - June 10, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news
Using DCIS Score To Quantify Risk Of IBE For Breast Cancer Patients
The ductal carcinoma in situ (DCIS) Score quantifies the risk of ipsilateral breast event (IBE) and invasive IBE risk, complements both traditional clinical and pathologic factors, and helps provide a new clinical tool to improve the process of selecting individualized treatment for women with DCIS who meet the criteria, according to a study published in the Journal of the National Cancer Institute. Most women with newly diagnosed cases of DCIS are eligible for breast conservation surgery, either with radiation treatment or without... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 6, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
DCIS Score quantifies risk of IBE
(Journal of the National Cancer Institute) The ductal carcinoma in situ (DCIS) Score quantifies the risk of ipsilateral breast event (IBE) and invasive IBE risk, complements both traditional clinical and pathologic factors, and helps provide a new clinical tool to improve the process of selecting individualized treatment for women with DCIS who meet the criteria, according to a study published May 2 in the Journal of the National Cancer Institute. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 2, 2013 Category: Global & Universal Source Type: news
Heterogeneity Quantified In Early Stage Breast-Cancer, Which Ultimately Could Help Doctors To Eradicate It Before More Invasive Cancers Develop
A variety of mutations may give rise to breast cancer, but scientists generally assume that it starts off with just a few. That's because later-stage breast cancers tend to have more mutations - they are more heterogeneous - than early stage cancers. Now, new findings by scientists at Fox Chase Cancer Center demonstrate heterogeneity is prevalent even within legions of ductal carcinoma in situ (DCIS), the most common, earliest stage non-invasive breast cancer (stage 0)... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Molecular Markers in Breast Ductal Carcinoma In SituMolecular Markers in Breast Ductal Carcinoma In Situ
Next-generation sequencing is an exciting new tool for discovering novel potential therapeutic targets and candidate biomarkers in breast cancer, particularly ductal carcinoma in situ. Expert Review of Molecular Diagnostics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 27, 2013 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
In US, Even More DCIS Is Coming: What Should Be Done?In US, Even More DCIS Is Coming: What Should Be Done?
The incidence of ductal carcinoma in situ will continue to climb, experts say. How to manage patients is a matter of debate. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 12, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Age does not influence recurrence risk in early breast cancer patients
Young women with an early type of breast cancer called ductal carcinoma in situ do not have a greater risk of cancer recurrence after undergoing breast-conserving treatment than their older counterparts, study results show. (Source: MedWire News - Consumer Health)
Source: MedWire News - Consumer Health - June 29, 2009 Category: Consumer Health News Source Type: news
